Trifecta Capital Advisors LLC Lowers Stock Position in GRAIL, Inc. $GRAL

Trifecta Capital Advisors LLC trimmed its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 51.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,300 shares of the company’s stock after selling 8,750 shares during the quarter. Trifecta Capital Advisors LLC’s holdings in GRAIL were worth $429,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. N.E.W. Advisory Services LLC purchased a new position in shares of GRAIL in the 4th quarter valued at $26,000. Caitong International Asset Management Co. Ltd bought a new position in shares of GRAIL in the 4th quarter worth $28,000. Elyxium Wealth LLC purchased a new stake in shares of GRAIL during the 4th quarter worth $31,000. Comerica Bank lifted its stake in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the last quarter. Finally, Fifth Third Bancorp boosted its position in GRAIL by 15,733.3% during the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares in the last quarter.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Several law firms, including Rosen, Berger Montague, Schall, Faruqi & Faruqi, Levi & Korsinsky, and others, are reminding investors about the ongoing class action and the August 4, 2026 lead plaintiff deadline, keeping the legal issue in focus. Article Title
• Neutral Sentiment: Robbins LLP and other firms are urging stockholders who bought shares during the alleged class period to contact them for information about joining the lawsuit, suggesting the case is still actively being marketed to affected investors. Article Title
• Negative Sentiment: The core negative takeaway is that the lawsuit centers on the February 20, 2026 trial update, which reportedly erased more than $2.2 billion in market value and is now being framed as securities fraud, a headline that can weigh on investor sentiment. Article Title

Insiders Place Their Bets

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.83% of the company’s stock.

GRAIL Price Performance

GRAIL stock traded down $3.79 during midday trading on Friday, reaching $72.00. The company’s stock had a trading volume of 509,860 shares, compared to its average volume of 564,771. The stock has a market capitalization of $3.09 billion, a P/E ratio of -6.94 and a beta of 3.22. The stock’s 50-day simple moving average is $64.29 and its 200-day simple moving average is $70.02. GRAIL, Inc. has a 52-week low of $29.95 and a 52-week high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The business had revenue of $40.78 million for the quarter, compared to analyst estimates of $39.16 million. As a group, equities research analysts expect that GRAIL, Inc. will post -10.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GRAL has been the topic of several analyst reports. Wolfe Research initiated coverage on GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Robert W. Baird set a $70.00 price objective on shares of GRAIL in a research note on Wednesday, May 6th. TD Cowen increased their target price on shares of GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, The Goldman Sachs Group started coverage on shares of GRAIL in a research note on Friday, June 5th. They issued a “neutral” rating and a $60.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $67.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.